Novo and Pfizer are among the investors set to exit the Stanford spinout, which has set a $100m target for its initial public offering.
Bolt Biotherapeutics, a US-based oncology therapy spinout of Stanford University backed by property developer Nan Fung and pharmaceutical firms Pfizer and Novo, has filed to raise up to $100m in its initial public offering.
Founded in 2015, Bolt is developing antibody drug conjugates to treat cancer and will channel part of the IPO proceeds into advancing its lead product candidate, BDC-1001, through a phase 1/2 clinical trial for cancers expressing the HER2 protein.
The company aims to…
